WESTBROOK, Maine — Global veterinary diagnostics and software leader IDEXX Laboratories, Inc. has announced two major strategic moves: the expansion of its diagnostic platform in Europe and a flagship acquisition to deepen its artificial intelligence capabilities.
Together, the developments highlight IDEXX’s dual focus on advancing preventative diagnostic accuracy and reducing administrative burnout across veterinary practices.
Diagnostic Screening Expansion: Advanced Taeniid Parasite Detection
IDEXX has officially rolled out an update to its Faecal Dx™ antigen testing platform in the United Kingdom, incorporating direct detection for Taeniid tapeworms (Taenia spp. and Echinococcus spp.)
Strategic AI Acquisition: IDEXX Acquires CoVetAI
In a bid to lead the veterinary software ecosystem, IDEXX completed the acquisition of CoVetAI Inc., a pioneer in AI-native ambient listening and clinical workflow automation.
Strategic Impact & Platform Integration
-
Ambient AI Scribing: CoVet’s platform automatically listens to and transcribes veterinarian-client consultations, organizing notes directly into structured SOAP (Subjective, Objective, Assessment, Plan) medical records in real time.
-
Workflow Intelligence: The acquisition addresses the industry-wide veterinary staffing crisis by cutting manual documentation time, allowing clinical staff to spend more face-to-face time with patients.
-
Ecosystem Compatibility: IDEXX plans to integrate CoVet across its cloud-based practice management software ecosystem—which serves over 10,000 clinics globally—while maintaining support for third-party, non-IDEXX management systems.
